News by subject: Clinical Study

Theratechnologies Inc. ("Theratechnologies" or "the Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the...

Biogen Inc. and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an...

Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration...

Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery...

-- Levels of Ki67+ expression by CD8+ T cells and NK cells increased by 17-fold and 10-fold, respectively, in the third cohort (30 µg/kg dose) when compared to baseline -- NK cell / Treg and CD8+T cell / Treg ratios increased by 4.4-fold and 2.6...

The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population ? 440 adults and children 6 years and older with type 1 diabetes ? was more...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's U.S. Food & Drug...

Rakovina Therapeutics Inc. , a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting. A Media Snippet...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus") announced the results of the prespecified final progression-free survival ("PFS") analysis and the interim overall survival...

Core One Labs Inc. , , (the "Company" or "Core One") is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. ("Akome") through a research arrangement with Neuro-Zone Srl, ("Neuro-Zone") based in Bresso, Italy, has achieved...

Biogen Inc.  has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval. This is in line with the company's...

Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a leading trade publication directed at optometrists. The innovative eye care therapy creates a biological barrier to...

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported Study results are adequate to give an effect...

Biogen Inc.  announced that The Journal of Prevention of Alzheimer's Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for...

ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of...

Wesana Health Holdings Inc. ?("Wesana" or the "Company") , a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced that they have received a full written response...